Eli Lilly

News

Ro co-founder and chief executive Zach Reitano

Lilly adds another sales channel for obesity drug Zepbound

Telehealth firm Ro will offer low-cost, single-dose vials of Lilly's obesity drug Zepbound, the first alternative to the new LillyDirect DTC channel.

News

Lilly Kenosha County - Expansion Rendering

Lilly invests another $3bn in its manufacturing network

Lilly will spend $3 billion on a recently acquired Wisconsin plant for injectable medicines, including diabetes and obesity drugs.

News

Mounjaro cleared for NHS use, but patients may have to wait

Many patients can expect a long wait for access to Eli Lilly's obesity shot Mounjaro, even though it has been recommended for routine NHS use by NICE

News

Zepbound tops Wegovy in first head-to-head weight-loss trial

Eli Lilly is playing catch-up to Novo Nordisk in the fast-growing obesity therapy sector but has new data that could tip the balance in its favour.

News

Kisqali gets early breast cancer approval in Europe

Novartis' fast-growing breast cancer drug gets another growth driver as EU approves adjuvant use in patients with early-stage HR+, HER2- tumours

News

female scientist conducting experiment in a laboratory

Tirzepatide gets a big win in obesity-related heart failure

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the

Lilly adds another sales channel for obesity drug Zepbound

Lilly invests another $3bn in its manufacturing network

Mounjaro cleared for NHS use, but patients may have to wait

Zepbound tops Wegovy in first head-to-head weight-loss trial

Kisqali gets early breast cancer approval in Europe

Tirzepatide gets a big win in obesity-related heart failure

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Eli Lilly

Editor's Picks